David Tuveson

David Tuveson

Professor, M.D., Ph.D., Johns Hopkins University (1994)

Pancreatic cancer, experimental therapeutics, diagnostics, mouse models, cancer genetics

  • Tuveson Lab
    Summer 2016

  • Tuveson Lab

    CSHL – Fall 2014

  • Tuveson lab at Lustgarten walk
    Jones Beach, Long island 2014

  • Tuveson lab christmas party 2014

    December 2014, Yellow house

  • Tuveson Lab retreat 2014

About the Lab

The Tuveson lab uses mouse and human tissue models of neoplasia to explore the fundamental biology of these diseases and thereby identify new diagnostic and treatment strategies. The team’s main focus is pancreatic cancer, a lethal malignancy that has eluded clinical solutions despite intensive study. The lab’s approaches at CSHL run the gamut from designing new model systems of disease to inventing new therapeutic and diagnostic platforms for rapid evaluation in preclinical and clinical settings. For example, we have adopted a new method of culturing tissue fragments indefinitely in cell culture, enabling deep analysis with genetic and pharmacological probes. In addition, therapeutic experiments in mouse models have revealed an important role of redox metabolism and stromal interactions on influencing therapeutic response. This year, our lab used the mouse model system to identify the mechanism of a promising drug treatment for pancreatic cancer. We found that using the drug in combination with more standard chemotherapeutic drugs stopped the tumor growth and lengthened life span for the mice, suggesting that the combination therapy may help overcome the drug resistance that is so commonly found in cancers. Tuveson’s lab also has a strong link to clinical trials locally and internationally, with confirmation in early-phase trials the ultimate goal. Collectively, our strategy in the preclinical and clinical arena is codified as the “Cancer Therapeutics Initiative,” and this initiative will provide these same approaches to the entire CSHL cancer community.